Claims for Patent: 9,994,550

Summary for Patent: 9,994,550

Title:	Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
Abstract:	Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds.
Inventor(s):	Wagman; Allan S. (Belmont, CA), Johnson; Russell J. (Sunnyvale, CA), Zaharia; Cristiana A. (Redwood City, CA), Cai; Haiying (Cupertino, CA), Hu; Lily W. (Palo Alto, CA), Duke; Greg (Menlo Park, CA), Ohol-Gupta; Yamini (Menlo Park, CA), Heuer; Timothy (Menlo Park, CA), O\'Farrell; Marie (Menlo Park, CA)
Assignee:	3-V Biosciences, Inc. (Menlo Park, CA)
Application Number:	15/110,154
Patent Claims:	1. A compound of Formula I: ##STR00040## or a pharmaceutically acceptable salt thereof, wherein: L-Ar is ##STR00041## Ar is ##STR00042## R.sup.1 is H, --CN, halogen, C.sub.1-C.sub.4 alkyl, --O--(C.sub.3-C.sub.5 cycloalkyl), --O-(4- to 6-membered heterocycle) or --O--(C.sub.1-C.sub.4 alkyl), wherein when R.sup.1 is not H, --CN or halogen, R.sup.1 is optionally substituted with one or more halogen; each R.sup.2 is independently hydrogen, halogen or C.sub.1-C.sub.4 alkyl; R.sup.3 is H or F; R.sup.21 is H, halogen, C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.5 cycloalkyl or 4- to 6-membered heterocycle; R.sup.22 is H, halogen or C.sub.1-C.sub.2 alkyl; R.sup.24 is --O--(C.sub.1-C.sub.4 alkyl), --O--(C.sub.1-C.sub.4 alkyl)-O--(C.sub.1-C.sub.4 alkyl), --O--(C.sub.3-C.sub.5 cycloalkyl), or --O-(4- to 6-membered heterocycle), wherein R.sup.24 is optionally substituted with one or more hydroxyl or halogen; and R.sup.25 is H, halogen, C.sub.1-C.sub.4 alkyl or C.sub.3-C.sub.5 cycloalkyl, wherein R.sup.25 is optionally substituted with one or more halogen; wherein the compound is not: ##STR00043## 2. The compound of claim 1, wherein L-Ar is ##STR00044## 3. The compound of claim 1, wherein L-Ar is ##STR00045## 4. The compound of claim 1, wherein L-Ar is ##STR00046## 5. The compound of claim 1, wherein R.sup.3 is H. 6. The compound of claim 1, wherein R.sup.1 is --CN or --O--(C.sub.1-C.sub.4 alkyl), wherein when R.sup.1 is not --CN, R.sup.1 is optionally substituted with one or more halogen; or R.sup.1 is --CN; or R.sup.1 is --O--(C.sub.1-C.sub.4 alkyl) optionally substituted with one or more halogen. 7. The compound of claim 1, wherein each R.sup.2 is hydrogen. 8. The compound of claim 1, wherein R.sup.21 is C.sub.1-C.sub.4 alkyl. 9. The compound claim 1, wherein R.sup.22 is H or C.sub.1-C.sub.2 alkyl. 10. The compound of claim 1, wherein R.sup.24 is --O--(C.sub.1-C.sub.4 alkyl) optionally substituted with one or more hydroxyl or halogen; or R.sup.24 is --O--(C.sub.1-C.sub.4 alkyl) optionally substituted with one or more hydroxyl. 11. The compound of claim 1, wherein R.sup.25 is --CH.sub.3. 12. The compound of claim 1, having one of the following structures: ##STR00047## ##STR00048## ##STR00049## ##STR00050## 13. The compound of claim 1, wherein the compound is: ##STR00051## 14. The compound of claim 1, wherein the compound is: ##STR00052## 15. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent. 16. A method of treating a condition characterized by disregulation of a fatty acid synthase pathway in a subject by administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the condition characterized by disregulation of a fatty acid synthase pathway is a cancer. 17. The method of claim 16, wherein the cancer is selected from the group consisting of breast cancer; mantle cell lymphoma; renal cell carcinoma; acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML); diffuse large B cell lymphoma (DLBCL); sarcoma; rhabdomyosarcoma; ovarian cancer; endometrial tumors; non small cell lung carcinoma (NSCLC); small cell, squamous, large cell and adenocarcinoma; lung cancer; colon cancer; colorectal tumors; KRAS-mutated colorectal tumors; gastric carcinomas; hepatocellular tumors; liver tumors; primary melanomas; pancreatic cancer; prostate carcinoma; thyroid carcinoma; follicular thyroid carcinoma; anaplastic large cell lymphoma (ALCL); hamaratomas, angiomyelolipomas, TSC-associated and sporadic lymphangioleiomyomatosis: Cowden's disease (multiple hamaratoma syndrome); sclerosing hemangioma; Peutz-Jeghers syndrome (PJS); head and neck cancer; neurofibromatosis; macular degeneration; macular edema; myeloid leukemia; systemic lupus; and autoimmune lymphoproliferative syndrome (ALPS). 18. The method of claim 17, further comprising administering a second therapeutic agent, wherein the second therapeutic agent is a cancer therapeutic agent selected from paclitaxel, doxorubicin, vincristine, actinomycin D, altretamine, asparaginase, bleomycin, busulphan, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitozantrone, oxaliplatin, procarbazine, steroids, streptozocin, taxotere, tamozolomide, thioguanine, thiotepa, tomudex, topotecan, treosulfan, uracil-tegufur, vinblastine, vindesine, nivolumab, pembrolizumab, MPDL3280A, MEDI4736, olaparib, erlotinib, necitumumab, traztuzamab, pertuzamab, lapatinib, crizotinib, cabozantinib, onartuamab, ramucirumab, bevacizumab, enzalutamide, abiraterone, tamoxifen, cobimetinib, vemurafenib, everolimus, lapatinib, trastuzumab, Kadyzla, sirolimus, avastin, nexavar, sutent, exemtesane, femora, enzalutamide, bicalutamide, Tafinlar, and Zelboraf.

Details for Patent 9,994,550

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2034-01-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2034-01-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2034-01-07
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2034-01-07
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	04/21/2014		2034-01-07
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2034-01-07